COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > The unexpected

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Aug 27, 2024 8:50am

48 Views

Post# 36197364

RE:RE:The unexpected

Schellaj wrote: And yet CSCI is down almost 50% on the American market this morning.

Macimorelin is a key asset and could finance the path forward. Is it the asset the US knows most about and the response of the market to this news may therefore overweight its significance? What is strategy B given these results? Is the rest of the company only worth ~C$15 million given the cash and other assets? We need to see a plan forward and the full analysis and path forward for macimorelin.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Sept. 19, 2024